{"id":9538,"date":"2026-02-24T23:28:30","date_gmt":"2026-02-24T15:28:30","guid":{"rendered":"https:\/\/regask.com\/?p=9538"},"modified":"2026-02-24T23:28:30","modified_gmt":"2026-02-24T15:28:30","slug":"la-nhra-de-bahrein-publica-la-version-3-2-de-la-guia-actualizada-sobre-variaciones-de-medicamentos-para-medicamentos-humanos","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","title":{"rendered":"La NHRA de Bahr\u00e9in publica una gu\u00eda actualizada sobre variaciones de medicamentos\u2026"},"content":{"rendered":"<p>En <strong>21 de enero de 2026,<\/strong> el <strong>Autoridad Nacional de Regulaci\u00f3n Sanitaria (NHRA)<\/strong> public\u00f3 una actualizaci\u00f3n <strong>Gu\u00eda de variaciones de medicamentos para medicamentos humanos.<\/strong> La directriz, <strong>Versi\u00f3n 3.2 (enero de 2026),<\/strong> se aplica a <strong>Medicamentos humanos con una autorizaci\u00f3n de comercializaci\u00f3n v\u00e1lida de la NHRA<\/strong> y establece los requisitos reglamentarios para la gesti\u00f3n<strong> variaciones posteriores a la aprobaci\u00f3n,<\/strong> incluyendo clasificaci\u00f3n, v\u00edas de presentaci\u00f3n, documentaci\u00f3n, plazos de evaluaci\u00f3n y expectativas de implementaci\u00f3n.<\/p>\n<div class=\"row\"  id=\"row-530000182\">\n\n\t<div id=\"col-1114402675\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-672784676\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-672784676 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Detalles de la actualizaci\u00f3n<\/h2>\n\t<div id=\"gap-1513952408\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1513952408 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La directriz actualizada se aplica a <strong>cambios realizados en los medicamentos humanos<\/strong> que ya cuentan con una autorizaci\u00f3n de comercializaci\u00f3n de la NHRA y una licencia v\u00e1lida. Explica c\u00f3mo se clasifican las variaciones posteriores a la aprobaci\u00f3n en <strong>Tipo IA, Tipo IB, <\/strong>y<strong> Tipo II,<\/strong> distinguir los cambios menores de aquellos que pueden afectar significativamente <strong>calidad, seguridad o eficacia.\u00a0<\/strong><\/p>\n<p>La directriz aclara que <strong>Variaciones del tipo IA<\/strong> seguir un enfoque de \u201chacer y contar\u201d, que permite la implementaci\u00f3n sin aprobaci\u00f3n previa pero requiere <strong>notificaci\u00f3n dentro de los 60 d\u00edas h\u00e1biles<\/strong> despu\u00e9s de su implementaci\u00f3n, con posibilidad de rechazo si no se cumplen las condiciones. <strong>Variaciones del tipo IB<\/strong> se manejan bajo un proceso de \u201cDecir, esperar y hacer\u201d, mientras que <strong>Variaciones de tipo II<\/strong> cubrir cambios importantes que requieren una evaluaci\u00f3n completa antes de su implementaci\u00f3n.<\/p>\n<p>Todas las solicitudes de variaci\u00f3n deben presentarse a trav\u00e9s de <strong>Sistema en l\u00ednea NHRA Adweya,<\/strong> usando <strong>Documento T\u00e9cnico Com\u00fan Electr\u00f3nico (eCTD)<\/strong> secuencias. La directriz especifica las expectativas de documentaci\u00f3n, incluyendo <strong>cartas de presentaci\u00f3n, comparaciones entre los estados actuales y propuestos,<\/strong> y <strong>aprobaciones o pruebas del pa\u00eds de origen,<\/strong> donde se aplica.<\/p>\n<p>En t\u00e9rminos de plazos reglamentarios, la NHRA establece per\u00edodos de finalizaci\u00f3n de evaluaci\u00f3n esperados de <strong>7 d\u00edas h\u00e1biles para el Tipo IA<\/strong> variaciones y <strong>40 d\u00edas h\u00e1biles para Tipo IB y Tipo II<\/strong> variaciones. Para los cambios aprobados, la directriz se\u00f1ala que <strong>Las variaciones de Tipo IB y Tipo II deben implementarse dentro de los 12 meses<\/strong> a partir de la fecha de la carta de aprobaci\u00f3n.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1114402675 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-264147616\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Fecha de entrada en vigor<\/h2>\n\t<div id=\"gap-465166913\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-465166913 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>El <strong>La Gu\u00eda de Variaciones de Medicamentos (Versi\u00f3n 3.2) entra en vigencia a partir del 21 de enero de 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-264147616 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1250712927\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Por qu\u00e9 es importante<\/h2>\n\t<div id=\"gap-13692093\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-13692093 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Esta actualizaci\u00f3n proporciona una alineaci\u00f3n regulatoria m\u00e1s clara sobre c\u00f3mo deben clasificarse, presentarse, revisarse e implementarse en Bahr\u00e9in los cambios posteriores a la aprobaci\u00f3n de medicamentos humanos. Al definir <strong>requisitos de presentaci\u00f3n digital, plazos estandarizados y ventanas de implementaci\u00f3n,<\/strong> La directriz apoya un procesamiento regulatorio m\u00e1s eficiente al tiempo que mantiene los controles de cumplimiento y minimiza la incertidumbre administrativa para los titulares de autorizaciones de comercializaci\u00f3n.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1250712927 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1277730059\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Para qui\u00e9n es relevante<\/h2>\n\t<div id=\"gap-34909226\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-34909226 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Esta actualizaci\u00f3n es relevante para <strong>Equipos de Asuntos Regulatorios, Garant\u00eda de Calidad, Cumplimiento, CMC y TI u operaciones regulatorias<\/strong> Responsable de gestionar los cambios posteriores a la aprobaci\u00f3n y las presentaciones electr\u00f3nicas de medicamentos humanos autorizados en Bahr\u00e9in.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1277730059 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-447502905\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pr\u00f3ximos pasos<\/h2>\n\t<div id=\"gap-1400406012\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1400406012 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Las empresas deber\u00edan revisar sus <strong>procedimientos de gesti\u00f3n de variaciones<\/strong> para garantizar la conformidad con los requisitos actualizados de la NHRA. Esto incluye confirmar la correcci\u00f3n <strong>clasificaci\u00f3n de variaciones,<\/strong> reuni\u00f3n <strong>Plazos de notificaci\u00f3n de tipo IA,<\/strong> preparante <strong>Presentaciones que cumplen con el eCTD<\/strong> a trav\u00e9s del sistema Adweya y ajustando los flujos de trabajo internos para cumplir con los requisitos establecidos <strong>Cronogramas de evaluaci\u00f3n e implementaci\u00f3n. <\/strong><\/p>\n<p><span class=\"TextRun SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">A medida que las organizaciones se adaptan a estos requisitos actualizados posteriores a la aprobaci\u00f3n,\u00a0<\/span><\/span><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/span><\/strong><\/a><span class=\"TextRun SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">\u00a0Puede respaldar una gesti\u00f3n del cumplimiento m\u00e1s estructurada y proactiva.\u00a0<\/span><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW200731050 BCX0\"> es una plataforma l\u00edder de inteligencia regulatoria y orquestaci\u00f3n de flujo de trabajo con inteligencia artificial (IA) que permite a las organizaciones globales en sectores altamente regulados, incluidos productos de consumo y ciencias biol\u00f3gicas, navegar de manera proactiva en panoramas regulatorios complejos. <strong>Al combinar la IA avanzada de Agentic con expertos en el sector, <\/strong><\/span><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW200731050 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW200731050 BCX0\">\u00a0entrega\u00a0<\/span><span class=\"NormalTextRun SCXW200731050 BCX0\">oportuno<\/span><span class=\"NormalTextRun SCXW200731050 BCX0\"> informaci\u00f3n predictiva y procesable y automatizaci\u00f3n de extremo a extremo, agilizando los procesos de cumplimiento, mitigando riesgos y acelerando el acceso al mercado en m\u00e1s de 160 pa\u00edses. <\/span><\/span><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">M\u00e1s informaci\u00f3n <\/span><\/span><\/strong><\/a><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\">o<\/span><\/span><a href=\"https:\/\/regask.com\/es\/reservar-una-demostracion\/\"><strong><span class=\"TextRun MacChromeBold SCXW200731050 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW200731050 BCX0\"> Reserve una demostraci\u00f3n ahora.<\/span><\/span><\/strong><\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-447502905 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1529338331\">\n\n\t<div id=\"col-1414557896\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>Preguntas frecuentes<\/h3>\n\t<div id=\"gap-358290520\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-358290520 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>\u00bfQu\u00e9 es la Gu\u00eda de Variaciones de Medicamentos de la NHRA de Bahr\u00e9in?<\/h4>\n\t<div id=\"gap-1693059288\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1693059288 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Es una directriz oficial emitida por la NHRA de Bahr\u00e9in que define c\u00f3mo deben clasificarse, presentarse, revisarse e implementarse los cambios posteriores a la aprobaci\u00f3n de medicamentos humanos autorizados.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1414557896 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1718073897\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfQu\u00e9 tipos de variaciones est\u00e1n contempladas en la directriz?<\/h4>\n\t<div id=\"gap-1069015139\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1069015139 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>La directriz cubre <strong>Tipo IA, Tipo IB, <\/strong>y<strong> Tipo II<\/strong> variaciones, que van desde cambios menores hasta cambios importantes que pueden afectar la calidad, la seguridad o la eficacia.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1718073897 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-629323901\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfC\u00f3mo deben presentarse las solicitudes de variaci\u00f3n a la NHRA?<\/h4>\n\t<div id=\"gap-890581516\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-890581516 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Todas las solicitudes de variaci\u00f3n deben presentarse a trav\u00e9s de <strong>Sistema en l\u00ednea Adweya de la NHRA que utiliza secuencias eCTD,<\/strong> junto con la documentaci\u00f3n de respaldo requerida.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-629323901 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1604020030\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>\u00bfC\u00f3mo puede RegASK ayudar a las empresas a gestionar las variaciones posteriores a la aprobaci\u00f3n de la NHRA?<\/h4>\n\t<div id=\"gap-1545558689\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1545558689 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong><a href=\"http:\/\/regask.com\/es\/\">RegASK<\/a><\/strong> ayuda a los equipos a realizar un seguimiento de las actualizaciones regulatorias, alinear los flujos de trabajo internos con los requisitos de variaci\u00f3n y administrar el env\u00edo de preparaci\u00f3n a trav\u00e9s de inteligencia regulatoria impulsada por IA y orquestaci\u00f3n de cumplimiento.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1604020030 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On January 21, 2026, the National Health Regulatory Authority (NHRA) published an updated Medicine Variations Guideline for Human Medicines. The guideline, Version 3.2 (January 2026), applies to human medicines with a valid NHRA marketing authorization and sets out the regulatory requirements for managing post-approval variations, including classification, submission pathways, documentation, assessment timelines, and implementation expectations.<\/p>","protected":false},"author":43,"featured_media":9539,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,533,35],"tags":[],"class_list":["post-9538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-middle-east","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bahrain NHRA Publishes Updated Medicine Variations<\/title>\n<meta name=\"description\" content=\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/la-nhra-de-bahrein-publica-la-version-3-2-de-la-guia-actualizada-sobre-variaciones-de-medicamentos-para-medicamentos-humanos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bahrain NHRA Publishes Updated Medicine Variations Guideline for Human Medicines (Version 3.2)\" \/>\n<meta property=\"og:description\" content=\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/la-nhra-de-bahrein-publica-la-version-3-2-de-la-guia-actualizada-sobre-variaciones-de-medicamentos-para-medicamentos-humanos\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T15:28:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"Bahrain NHRA Publishes Updated Medicine Variations Guid&hellip;\",\"datePublished\":\"2026-02-24T15:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"},\"wordCount\":806,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"articleSection\":[\"Regulatory News\",\"Middle East\",\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\",\"name\":\"Bahrain NHRA Publishes Updated Medicine Variations\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"datePublished\":\"2026-02-24T15:28:30+00:00\",\"description\":\"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png\",\"width\":800,\"height\":600,\"caption\":\"Bahrain Nhra Publishes Updated Medicine Variations Guideline Human Medicines Version 3 2\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La NHRA de Bahr\u00e9in publica variaciones actualizadas de medicamentos","description":"La NHRA de Bahr\u00e9in publica la Gu\u00eda actualizada sobre variaciones de medicamentos para medicamentos humanos, versi\u00f3n 3.2, que describe los cambios regulatorios clave.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/la-nhra-de-bahrein-publica-la-version-3-2-de-la-guia-actualizada-sobre-variaciones-de-medicamentos-para-medicamentos-humanos\/","og_locale":"es_ES","og_type":"article","og_title":"Bahrain NHRA Publishes Updated Medicine Variations Guideline for Human Medicines (Version 3.2)","og_description":"Bahrain NHRA publishes updated Medicine Variations Guideline for Human Medicines, Version 3.2, outlining key regulatory changes.","og_url":"https:\/\/regask.com\/es\/la-nhra-de-bahrein-publica-la-version-3-2-de-la-guia-actualizada-sobre-variaciones-de-medicamentos-para-medicamentos-humanos\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-02-24T15:28:30+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#article","isPartOf":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"Bahrain NHRA Publishes Updated Medicine Variations Guid&hellip;","datePublished":"2026-02-24T15:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"},"wordCount":806,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","articleSection":["Regulatory News","Middle East","Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","url":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/","name":"La NHRA de Bahr\u00e9in publica variaciones actualizadas de medicamentos","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","datePublished":"2026-02-24T15:28:30+00:00","description":"La NHRA de Bahr\u00e9in publica la Gu\u00eda actualizada sobre variaciones de medicamentos para medicamentos humanos, versi\u00f3n 3.2, que describe los cambios regulatorios clave.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/bahrain-nhra-publishes-updated-medicine-variations-guideline-for-human-medicines-version-3-2\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/02\/bahrain-nhra-publishes-updated-medicine-variations-guideline-human-medicines-version-3-2.png","width":800,"height":600,"caption":"Bahrain Nhra Publishes Updated Medicine Variations Guideline Human Medicines Version 3 2"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=9538"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/9539"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=9538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=9538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=9538"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}